Ole S. Søgaard

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

Thomas A. Rasmussen, Martin Tolstrup, Christel R. Brinkmann et al. · The Lancet HIV · 2014 · 641 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

Ole S. Søgaard, Mette E. Graversen, Steffen Leth et al. · PLoS Pathogens · 2015 · 523 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith et al. · EBioMedicine · 2021 · 398 citations · Full text

Life Sciences, Infectious Diseases, Medicinal Chemistry +16

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

Boris Jülg, Lynda Dee, Jintanat Ananworanich et al. · The Lancet HIV · 2019 · 206 citations

Pharmacy, Pharmacotherapy, Good Clinical Practice +12

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.

Jesper Damsgaard Gunst, Marie H. Pahus, Lena Hagelskjær Kristensen et al. · EClinicalMedicine · 2021 · 197 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +3